110 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
are evaluating the safety, efficacy and pharmacokinetics of different doses of atumelnant in participants with CAH and Cushing’s disease.
Submission of a New Drug … development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of an NDA
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
Safety and Efficacy Findings
SAN DIEGO – May 8, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced five abstracts from its clinical … in development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. One presentation will showcase initial safety and key
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Automatic shelf registration
4:05pm
treatment options have significant efficacy, safety and/or tolerability limitations. Our product candidates include paltusotine (formerly CRN00808 … , multi-center Phase 2 study to assess the safety and pharmacokinetics of multiple doses of paltusotine in people living with carcinoid syndrome
8-K
EX-99.2
kmu j8ogty2
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
v70 wzxvzff
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.1
1dulgb95
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
u61e06c0
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-99.2
h4h6xi8f84nj0ojr7w
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-99.1
7u5bs2
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
z35o7eoebzxzhafeot8g
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
eji2z
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
y13dn5e5oj7xh
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
wb0v9xb2n1s34c4fs
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.1
xi133duuqew
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.2
kcrf2uth2
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
qezo0f7f
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
7fe9otp6q5gbhfdeyf4
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm